The P95 Julius Clinical team recently joined researchers, sponsors, clinicians, and industry leaders in Munich for ESC Congress 2026. Across scientific sessions, new clinical guidance, and industry discussions, several themes emerged that could in...
Real-world evidence (RWE) can help neuroscience sponsors account for disease heterogeneity, identify development risks earlier, and build more precise evidence strategies from Day 1.For decades, Parkinson’s disease has often been approached ...
A Science-Led CRO Partner for Complex Cardiometabolic Clinical Trials Cardiometabolic diseases rarely occur in isolation. Obesity, diabetes, cardiovascular disease, chronic kidney disease, lipid disorders, and metabolic liver disease share interc...
With obesity affecting more than one billion people globally and the market for obesity therapeutics projected to grow dramatically over the next decade, the stakes for sponsors have never been higher. Driven by breakthrough therapies, rapid marke...
Drawing on the experience and perspectives of Prof. Dr. Manuel Castro Cabezas, Scientific Officer at P95 Julius Clinical, and Prof. Dr. Diederick (Rick) E. Grobbee, Chief Scientific Officer at P95 Julius Clinical, this article explores how sponsor...
Patient recruitment remains one of the most persistent challenges in clinical research. Yet in neuroscience, the challenge is rarely just about finding enough participants. Increasingly, it is about identifying the right patients at the right stag...
LAP-defined Hepatic Steatosis and Cardiometabolic Risk in Rheumatoid Arthritis: A Post-hoc Analysis of the FRANCIS Randomized TrialPatients with rheumatoid arthritis (RA) face an increased risk of cardiovascular disease, driven by a complex in...
Rescuing a Stalled Cardiovascular Outcomes Trial Through Targeted Operational Intervention When a Phase III cardiovascular outcomes trial (CVOT) faced significant enrollment delays and timeline risk, Julius Clinical was engaged to support and acc...
Executing a Complex Phase III Diabetes Cardiovascular Outcomes Trial in a High-Risk Population Cardiovascular outcomes trials (CVOTs) in type 2 diabetes present a unique combination of clinical, operational, and regulatory complexity, particularl...
Ubiquitous in real-world data (RWD) projects, Electronic Medical Record (EMR) and Electronic Health Record (EHR) data is making its way slowly but surely into clinical trials, and the possibilities appear endless… what’s the current situation,...
"*" indicates required fields
"*" indicates required fields
